Realm Therapeutics Plc (LON:RLM): Does -39.96% Earnings Drop In A Year Reflect The Long-Term Trend?

For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find my commentary, albeit very high-level and brief, on Realm Therapeutics Plc (AIM:RLM) useful as an attempt to give more color around how Realm Therapeutics is currently performing. View our latest analysis for Realm Therapeutics

Did RLM perform worse than its track record and industry?

For the most up-to-date info, I use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. This technique enables me to examine various companies on a similar basis, using the most relevant data points. For Realm Therapeutics, its most recent earnings (trailing twelve month) is -US$8.49M, which, relative to last year’s figure, has become more negative. Since these values are relatively myopic, I’ve created an annualized five-year value for RLM’s net income, which stands at -US$6.48M. This doesn’t seem to paint a better picture, since earnings seem to have consistently been getting more and more negative over time.

AIM:RLM Income Statement Mar 5th 18
AIM:RLM Income Statement Mar 5th 18
We can further assess Realm Therapeutics’s loss by looking at what the industry has been experiencing over the past few years. Each year, for the past half a decade Realm Therapeutics has seen an annual decline in revenue of -36.10%, on average. This adverse movement is a driver of the company’s inability to reach breakeven. Has the entire industry experienced this headwind? Looking at growth from a sector-level, the UK pharmaceuticals industry has been growing its average earnings by double-digit 43.79% in the prior twelve months, and 11.20% over the past five years. This means whatever tailwind the industry is benefiting from, Realm Therapeutics has not been able to gain as much as its industry peers.

What does this mean?

Though Realm Therapeutics’s past data is helpful, it is only one aspect of my investment thesis. Companies that incur net loss is always hard to predict what will happen in the future and when. The most insightful step is to examine company-specific issues Realm Therapeutics may be facing and whether management guidance has consistently been met in the past. I suggest you continue to research Realm Therapeutics to get a better picture of the stock by looking at:

  • 1. Financial Health: Is RLM’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
  • 2. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
NB: Figures in this article are calculated using data from the trailing twelve months from 30 June 2017. This may not be consistent with full year annual report figures.